Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Agenus Inc.
Agenus Inc along with its subsidiaries is a pharmaceutical company. It is engaged in discovery and development of revolutionary new treatments that engage the body's immune system to benefit patients suffering from cancer.
IPO Date: February 4, 2000
Sector: Healthcare
Industry: Biotech
Market Cap: $140.92M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.12 | 3.43%
Avg Daily Range (30 D): $0.25 | 6.02%
Avg Daily Range (90 D): $0.17 | 5.70%
Institutional Daily Volume
Avg Daily Volume: 1.41M
Avg Daily Volume (30 D): 1.18M
Avg Daily Volume (90 D): .73M
Trade Size
Avg Trade Size (Sh.): 283
Avg Trade Size (Sh.) (30 D): 140
Avg Trade Size (Sh.) (90 D): 140
Institutional Trades
Total Inst.Trades: 1,266
Avg Inst. Trade: $1.67M
Avg Inst. Trade (30 D): $1.01M
Avg Inst. Trade (90 D): $1.01M
Avg Inst. Trade Volume: .03M
Avg Inst. Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $1.76M
Avg Closing Trade (30 D): $1.07M
Avg Closing Trade (90 D): $1.07M
Avg Closing Volume: 36.02K
   
News
Jun 13, 2025 @ 1:48 PM
Neoantigen Cancer Vaccines Industry Analysis Repor...
Source: Researchandmarkets.Com
Feb 12, 2025 @ 6:00 PM
MiNK Therapeutics to Present Updated Data from Pha...
Source: N/A
Jan 23, 2025 @ 7:13 PM
MiNK Therapeutics Targets Immune Reconstitution to...
Source: N/A
Nov 12, 2024 @ 5:15 PM
Agenus (AGEN) Q3 2024 Earnings Call Transcript
Source: The Motley Fool
Nov 2, 2024 @ 11:45 AM
DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages In...
Source: Faruqi & Faruqi, Llp
Financials
  TTM Q4 2024 FY 2024
Basic EPS $-10.59 $-1.94 $-10.59
Diluted EPS $-10.59 $-1.94 $-10.59
Revenue $ 103.46M $ 26.84M $ 103.46M
Gross Profit $ 102.98M $ 26.72M $ 102.98M
Net Income / Loss $ -232.27M $ -46.81M $ -232.27M
Operating Income / Loss $ -120.48M $ -25.9M $ -120.48M
Cost of Revenue $ .49M $ .12M $ .49M
Net Cash Flow $ -35.45M $ -4.3M $ -35.45M
PE Ratio    
Splits
Apr 12, 2024:   1:20
Oct 03, 2011:   1:6